Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.

ABSTRACT: Subsequent malignancies are well-documented complications in long-term follow-up of cancer patients. Recently, genetically modified immune effector (IE) cells have shown benefit in hematologic malignancies and are being evaluated in clinical trials for solid tumors. Although the short-term complications of IE cells are well described, there is limited literature summarizing long-term follow-up, including subsequent malignancies. We retrospectively reviewed data from 340 patients treated across 27 investigator-initiated pediatric and adult clinical trials at our center. All patients received IE cells genetically modified with γ-retroviral vectors to treat relapsed and/or refractory hematologic or solid malignancies. In a cumulative 1027 years of long-term follow-up, 13 patients (3.8%) devel

SUBMITTER: Steffin DHM 

PROVIDER: S-EPMC9346960 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature